NEW YORK (GenomeWeb News) - Rules-Based Medicine and EMD Chemicals said today that they are partnering to develop and distribute immunoassay products for use on Luminex’s xMAP platform.
 
Under the terms of the agreement, biomarker testing firm RBM is providing EMD, a subsidiary of Germany’s Merck KGaA, exclusive distribution rights to its catalog of quantitative protein multiplex assays.
 
EMD will market RBM’s testing content in co-branded multi-analyte kits under its Novagen brand.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.